The immune adherence hemagglutination assay was found to be as sensitive and specific as the indirect immunofluorescence technique for titration of antibodies to Epstein-Barr virus capsid antigen. Satisfactory virus capsid antigen-specific and negative control antigens for the immune adherence hemagglutination assay were prepared from cell extracts of the Epstein-Barr virus producer P3HR-1 and the Epstein-Barr virus genome-negative BJAB lymphoblastoid cell lines, respectively. As the immune adherence hemagglutination assay can be used to titrate antibodies to both the heterophil antigen of the Paul-Bunnell type and to virus capsid antigen, it offers a promising alternative to the immunofluorescence methods in the serodiagnosis of Epstein-Barr virus infections which can be performed by most diagnostic laboratories.
Epstein-Barr virus (EBV) infections result in
responses ranging from asymptomatic seroconversion to infectious mononucleosis (IM), a lymphoproliferative disease which can have serious central nervous system and other complications (2, 6, 11) . IM-like illnesses are caused also by other infectious agents such as cytomegalovirus, adenovirus, and several other viruses or Toxoplasma gondii. At present, the serological method most widely used to diagnose IM is the test for heterophil antibodies of the Paul-Bunnell type. A positive heterophil antibody test is considered diagnostic for IM in patients who present with the typical clinical and hematological picture of the disease. However, in patients without heterophil antibody responses, with an atypical course of illness, or with complications, EBV-specific serological tests are required for establishing the diagnosis.
The indirect immunofluorescence assay (IFA) is presently the method most widely used to detect both EBV-specific antigens and antibodies in primary EBV infections. The fluorescence tests are specific and sensitive (5, 8) . Unfortunately, EBV-specific IFA procedures are complex and thus impractical for many diagnostic laboratories. Serodiagnosis by IFA depends on the presence of immunoglobulin M (IgM) and IgG antibodies to the virus capsid antigen (VCA) and to the D (diffuse) component of the early antigen (EA) complex, and on the absence of antibodies to the EBV-associated nuclear antigen (EBNA). Although cell smears suitable for the detection of IgG antibodies to VCA are becoming commercially available, they rarely t Present address: Virolab, Inc., Emeryville, CA 94608. suffice for diagnosis, because anti-VCA persists after the primary infection for life. In addition peak titers of antibodies to this antigen are often reached before the patient seeks medical attention so that diagnostically significant rises in titer are seen in fewer than 20% of the cases.
Current recommendations for the serodiagnosis of primary EBV infections involve a stepwise approach (9) . The test for Paul-Bunnell heterophil antibodies is frequently performed first, as it is highly specific for IM and is widely available. EBV-specific serology is often carried out for either confirmatory or exclusionary purposes. This approach creates difficulties for both the clinician and the laboratory: for the physician because it means a delay in diagnosis, as the EBV serology can be carried out in only a few laboratories; for the laboratory because the heterophil test is positive in only a fraction of the total number of tests requested, and if it is negative, no useful information is obtained on the immune status of the patient. Ideally, the test for heterophil and EBV-specific antibodies should be performed in the same diagnostic laboratory.
As part of efforts toward purification and characterization of EBV-determined antigens, our laboratory has been evaluating immunoassays for the detection of solubilized antigens and their corresponding antibodies. As reported previously, the immune adherence hemagglutination assay (IAHA) is possibly the most sensitive and specific assay for Paul-Bunnell heterophil antibodies (12) . This report shows that the IAHA technique is suitable also for the detection of antibodies to VCA and that the results obtained are closely comparable to those recorded (Fig. 1B) . As most of the sera contained neither anti-D nor anti-R, the reactions observed in the IAHA test were obviously unrelated to the EA components. In contrast, there was an excellent correlation between the IAHA titers and the IgG anti-VCA titers obtained by IFA (Fig. 1A) . The Sera from 58 patients with IM showed a fair correlation between the titers obtained by the IAHA and IFA methods (Fig. 2) . However, unlike the results obtained with the sera from individuals with past infections, the GMT of IM sera obtained by IAHA (1:328) was nearly twofold higher than the GMT obtained by the IFA technique (1: 192 Two types of nonspecific activity were observed with 6 of the total of 155 sera tested. The first was noted with 4 of the 58 IM sera which showed hemagglutination in the absence of any antigen and only in the presence of complement. However, these sera were unequivocally positive, as their EBV-specific IAHA titers were more than fourfold higher than the nonspecific titers in the serum control. The second type of nonspecific reactivity was seen with two sera which gave titers of 1:10 and 1:40 with both the positive (P3HR1) and the negative control The preparations of antigen used in the IAHA test undoubtedly contained a multitude of other EBV-induced antigens such as the D and R components of the EA complex and EBNA. However, these did not interfere with the determination of anti-VCA titers, judging from the excellent correlation between the antibody titers obtained by IFA and IAHA. This is not unexpected as antibodies to D, R, and EBNA are nearly always of lower titer than anti-VCA when measured by IFA. The presence of heterophil antigen in the fetal calf serum component of the tissue culture medium could also have presented a problem. However, any residual traces of heterophil antigen that might have remained after washing of the cells before preparation of the cell extracts did not interfere, as is evident from the failure of heterophil antibody-positive sera to react with the control BJAB cell extracts.
